UB Paderborn / Katalog / Suche / in CDI

Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial

PloS one, 2019-09, Vol.14 (9), p.e0222178

2019

Volltextzugriff (PDF)

DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial

PloS one, 2013-04, Vol.8 (4), p.e59340

2013

Volltextzugriff (PDF)

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)

PloS one, 2016-11, Vol.11 (11), p.e0166393

2016

Volltextzugriff (PDF)

DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial

PloS one, 2015-05, Vol.10 (5), p.e0125914

2015

Volltextzugriff (PDF)

Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)

PloS one, 2014-03, Vol.9 (3), p.e91366

2014

Volltextzugriff (PDF)

Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial

PloS one, 2014-09, Vol.9 (9), p.e106240-e106240

2014

Volltextzugriff (PDF)

Chimpanzee Adenovirus Vector Ebola Vaccine

The New England journal of medicine, 2017-03, Vol.376 (10), p.928-938

2017

Volltextzugriff (PDF)

Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2020-04, Vol.323 (14), p.1369

2020

Volltextzugriff (PDF)

Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection

Archives of virology, 2009, Vol.154 (7), p.1093-1099

2009

Volltextzugriff (PDF)

Phase 1 study of pandemic H1 DNA vaccine in healthy adults

PloS one, 2015-04, Vol.10 (4), p.e0123969-e0123969

2015

Volltextzugriff (PDF)

Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults

mAbs, 2017-07, Vol.9 (5), p.792-800

2017

Volltextzugriff (PDF)

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

The lancet respiratory medicine, 2021-10, Vol.9 (10), p.1111-1120

2021

Volltextzugriff (PDF)

Cross-Sectional Study on Nonmalignant Respiratory Morbidity due to Exposure to Synthetic Amorphous Silica

Journal of occupational and environmental medicine, 2016-04, Vol.58 (4), p.376-384

2016

Volltextzugriff (PDF)

External cause-specific summaries of occupational fatal injuries. Part I: An analysis of rates

American journal of industrial medicine, 2003-03, Vol.43 (3), p.237-250

2003

Volltextzugriff (PDF)

An alternate characterization of hazard in occupational epidemiology: Years of life lost per years worked

American journal of industrial medicine, 2002-07, Vol.42 (1), p.1-10

2002

Volltextzugriff (PDF)

Uncertainty in the Relation between Exposure to Magnetic Fields and Brain Cancer due to Assessment and Assignment of Exposure and Analytical Methods in Dose-Response Modeling

Annals of the New York Academy of Sciences, 1999-01, Vol.895 (1), p.141-155

1999

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial

DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)

DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial

Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial

Chimpanzee Adenovirus Vector Ebola Vaccine

Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial

Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

Phase 1 study of pandemic H1 DNA vaccine in healthy adults

Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

Cross-Sectional Study on Nonmalignant Respiratory Morbidity due to Exposure to Synthetic Amorphous Silica

External cause-specific summaries of occupational fatal injuries. Part I: An analysis of rates

An alternate characterization of hazard in occupational epidemiology: Years of life lost per years worked

Uncertainty in the Relation between Exposure to Magnetic Fields and Brain Cancer due to Assessment and Assignment of Exposure and Analytical Methods in Dose-Response Modeling

Aktive Filter

Suchergebnisse filtern